A systematic review of the antipsychotic properties of cannabidiol in humans

  title={A systematic review of the antipsychotic properties of cannabidiol in humans},
  author={Tabitha A Iseger and Matthijs G. Bossong},
  journal={Schizophrenia Research},

Tables from this paper

Could cannabidiol be used as an alternative to antipsychotics?
  • M. Fakhoury
  • Psychology, Medicine
    Journal of psychiatric research
  • 2016
The Impact of Cannabidiol on Human Brain Function: A Systematic Review
Neuroimaging studies have shown that acute CBD induces significant alterations in brain activity and connectivity patterns during resting state and performance of cognitive tasks in both healthy volunteers and patients with a psychiatric disorder.
The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
CBD, either as monotherapy or added to regular antipsychotic medication, improved symptoms in patients with schizophrenia, with particularly promising effects in the early stages of illness.
Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia, and preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings.
Cannabinoids and Schizophrenia: Risks and Therapeutic Potential
CBD may have therapeutic potential for the treatment of psychosis following cannabis use, as well as schizophrenia, possibly with better tolerability than current antipsychotic treatments, and CBD may also have anti-inflammatory and neuroprotective properties.
Prospects for the Use of Cannabinoids in Psychiatric Disorders
The prospects of using the psychoactive effects of cannabinoids in treating mental and psychiatric disorders are discussed, however, this evidence is weak for some clinical conditions and well-designed randomized controlled trials are currently lacking.
Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol
Future cannabis-related policy decisions should include consideration of scientific findings, including the individual and interactive effects of CBD and THC, as well as other cannabinoid molecules currently being evaluated for medicinal purposes, separately and in combination.
Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective
Given the growing popularity in the use of cannabinoid-based drugs and their harmful potential, there is a need for further research in this field.


A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
Δ(9)-tetrahydrocannabinol (Δ(9)-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to
Cannabidiol monotherapy for treatment-resistant schizophrenia
The preliminary data suggest that CBD monotherapy may not be effective for TRS, and patients with treatment-resistant schizophrenia should be switched to olanzapine for over 15 days.
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
It is suggested that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia.
Cannabidiol as a potential treatment for psychosis
Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies.
Results of neuroimaging studies that investigated acute and non-acute effects of cannabis on human learning and memory function, both in adults and in adolescents show that cannabis use is associated with a pattern of increased activity and a higher level of deactivation in different memory-related areas.
Cannabidiol for the treatment of psychosis in Parkinson’s disease
Preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD.
Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms
The results suggest that anandamide elevation in acute paranoid schizophrenia may reflect a compensatory adaptation to the disease state, and the endocannabinoids are a family of bioactive lipids that activate CB1 cannabinoid receptors in the brain and exert intense emotional and cognitive effects.
Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?
This overview of cognitive dysfunction associated with long-term or heavy cannabis use is examined in the context of the neurobiology underlying cognitive dysfunction, particularly implicating the endogenous cannabinoid system, which plays a significant role in attention, learning and memory, and in general, inhibitory regulatory mechanisms in the brain.
Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being
CBD attenuates the psychotic-like effects of cannabis over time in recreational users, and raises concerns for the harms stemming from use of varieties such as ‘skunk’ (sensimillia), which lack any CBD but currently dominate the supply of cannabis.
Elevated endogenous cannabinoids in schizophrenia.
Elevated anandamide and palmitylethanolamide levels in cerebrospinal fluid of schizophrenic patients may reflect an imbalance in endogenous cannabinoid signaling, which may contribute to the pathogenesis of schizophrenia.